AHMEDABAD, India, June 21, 2010 /PRNewswire/ — Zydus Cadila,
a global healthcare provider and one of India’s leading healthcare companies has
received Phase I clinical trial permission from the DCGI for ZYOG1
– a novel GLP-1 agonist. Designed and developed at the Zydus
Research Centre using a unique platform technology, ZYOG1 is a
novel, oral, anti-diabetic molecule.
The new class of anti-diabetic drugs called Glucagon Like
Peptide-1 (GLP -1) agonists came to the fore in May 2005 when the first molecule of this
class was approved by the USFDA. Glucagon Like Peptide-1 agonists
are being used to treat people with type 2 diabetes who have not
been able to control their blood sugar levels with oral medicines.
It is an injectible which acts like the natural hormones in the
body that lowers blood sugar.
ZYOG1 would represent a next generation GLP-1 agents, as it
would not have to be injected but can be taken orally. ZYOG1, when
administered by oral route demonstrated beneficial effects in
preclinical models on glucose reduction, HbA1c reduction and showed
an added benefit of weight loss. Additionally, ZYOG1 has displayed
a differentiated preclinical safety profile with no nausea-like
symptoms in the preclinical studies.
Speaking on the new development, Mr. Pankaj R. Patel, Chairman and Managing
Director, Zydus Cadila, said, “The discovery of the novel oral
GLP-1 agonist, ZYOG1, using our own unique, discovery platform
technology, is a significant achievement for us. This novel
molecule would address unmet medical needs in treating diabetes and
holds promising potential in the anti-diabetic and anti-obesity
market.”
The number of diabetics in
‘/>”/>
